AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease

Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX) announced progress in its epetraborole development for treatment-refractory Mycobacterium avium complex (MAC) lung disease. Data from a recent Phase 1 study in Japan supports a 500 mg daily dose. The clinical development strategy prioritizes Japan and the U.S., highlighting their high MAC lung disease prevalence. Additionally, the European Commission granted orphan medicinal product designation for epetraborole in NTM lung disease, providing market exclusivity and support for further development.

Positive

• Successful Phase 1 study in Japan supports a once-daily, 500 mg dosing of epetraborole.
• Focus on Japan and U.S. markets, which have the highest prevalence of MAC lung disease.
• Received orphan medicinal product designation from the European Commission for epetraborole, enhancing market position.

Negative

• None.

• Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once Daily, 500 mg Dose in Japanese Patients
  
• Treatment-Refractory MAC Lung Disease Clinical Development Strategy to Focus Initially on Japan and U.S., Two Countries with Highest Prevalence of MAC Lung Disease
• Epetraborole Granted Orphan Medicinal Product Designation in NTM Lung Disease in European Union
  

MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today provided an update on the ex-U.S. development plan for epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease, the most common form of non-tuberculous mycobacterial (NTM) lung disease.

“We believe that epetraborole has the potential to provide significant benefit to patients with NTM lung disease and are pleased with the progress we’ve made globally across our epetraborole development program, including, most recently, the results from our Phase 1 trial in Japan (EBO-103) that further validate data from our previous studies and support our recommended Phase 2/3 dose in the ongoing EBO-301 pivotal trial in treatment-refractory MAC patients,” said Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics. “These data are an important step towards including patients in our ongoing EBO-301 pivotal Phase 2/3 trial from Japan, a country with one of the highest prevalence rates of MAC lung disease in the world.”

Easom added, “In addition, the European Commission’s decision to adopt the orphan medicinal product designation for epetraborole for NTM lung disease is an important milestone. After discussion with the European Medicines Agency, we believe the clearest path to address the unmet medical need in Europe is through further development of epetraborole in patients with treatment-naïve MAC lung disease, which is in scope of this designation. We expect to provide further updates on our approach to this important patient population in the future.”

Results from Phase 1 PK/Safety Study of Oral Epetraborole in Japan (EBO-103)
This Phase 1 study was designed to evaluate the pharmacokinetics, safety, and tolerability of oral epetraborole administered as a single 500 mg dose to healthy Japanese volunteers with different alcohol dehydrogenase (ADH) genotypes. Results of the study showed that no subjects experienced treatment-emergent adverse events and support use of AN2’s recommended dose in Japanese patients enrolled in its ongoing Phase 2/3 study. Epetraborole exposures were similar amongst patients with different ADH genotypes, and consistent with those observed in non-Japanese subjects in a previously reported Phase 1 study (EBO-101).

European Union Orphan Medicinal Product Designation
In August, the Company received the orphan medicinal product designation for epetraborole in NTM lung disease from the European Commission, which grants orphan medicinal product designation to medicines intended for the treatment, prevention or diagnosis of a life-threatening or very serious condition, with a prevalence in the European Union of not more than five in 10,000 people, and where either no satisfactory method of diagnosis, prevention or treatment of the condition in question exists, or if such method exists that the medicinal product will be of significant benefit to those affected by that condition. The designation provides various incentives, including ten-year market exclusivity upon regulatory approval, if received, fee reductions, and access to protocol assistance.

About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. AN2 is developing epetraborole, a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: AN2's ability to provide significant benefits to patients with NTM lung disease, anticipated progress, business plans, business strategy and planned clinical trials; AN2's plans to include Japan in its Phase 2/3 pivotal clinical trial and the timing thereof; the potential clinical benefits and therapeutic potential of epetraborole; the ability to receive market exclusivity in the European Union; the ability of AN2’s clinical trials to support regulatory approval; and other statements that are not historical fact. These statements are based on AN2's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include those described under the heading “Risk Factors” in AN2's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the U.S. Securities and Exchange Commission (SEC). These filings, when available, are available on the investor relations section of our website at investor.an2therapeutics.com and on the SEC's website at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and AN2 undertakes no duty to update such information except as required under applicable law.

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT: 
Anne Bowdidge 
ir@an2therapeutics.com

FAQ

What were the results of the Phase 1 study for epetraborole in Japanese patients?

The Phase 1 study demonstrated that a 500 mg dose of epetraborole was well-tolerated with no treatment-emergent adverse events reported.

How does the orphan medicinal product designation affect AN2 Therapeutics?

The designation provides AN2 with market exclusivity for epetraborole in NTM lung disease, along with access to regulatory support and fee reductions.

What is AN2 Therapeutics' strategy for epetraborole?

The strategy focuses on developing epetraborole initially in Japan and the U.S., targeting treatment-refractory MAC lung disease patients.